Training the Immune System to Recognize Cancer Cells

Ian Walters, CEO of Portage Biotech, discusses the challenges facing immuno-oncology and the unique approach the company has taken.

Ian B. Walters, M.D., MBA

Chief Executive Officer & Director Dr. Ian Walters has over 20 years of leadership and expertise in oncology/immunology drug development and specializes in the evaluation, prioritization and innovation of new therapies for the treatment of severe diseases. Currently, he is the CEO of Portage Biotech. Prior to Portage, Ian spent seven years at Bristol Myers Squibb, where he managed physicians overseeing the international development of more than eight oncology compounds including nivolumab (anti-PD-1), ipilimumab (anti-CTLA-4), brivanib (anti VEGF/FGF), anti-IGF/IR, VEGFR2 biologic, elotuzumab (antiCS1) and biomarker and companion diagnostic work. He was a core member of Bristol Myers Squibb’s Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, clinical collaborations and the company’s immuno-oncology strategy. Prior to BMS, he held positions at PDL BioPharma, Inc., Millennium Pharmaceuticals, Inc. and Sorrento Therapeutics, Inc., leading corporate development, translational medicine, clinical development and medical affairs.

Q: